Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Lasa Supergenerics Ltd. Share Price
Day's Range
Day's Range
Low
₹6.84
High
₹7.20
Price Summary
| Previous Close | ₹7.01 |
|---|---|
| Day's Range | ₹6.84 - ₹7.20 |
| Open | ₹7.20 |
| 52 Week Range | ₹05.67 - ₹14.08 |
| Volume | 14,655 |
| Market Cap | ₹0.00 |
| Previous Close | ₹7.00 |
|---|---|
| Day's Range | ₹6.94 - ₹7.10 |
| Open | ₹7.10 |
| 52 Week Range | ₹05.65 - ₹14.14 |
| Volume | 622 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.03 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -6.80 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.71 |
| PAT Margin (%) | -20.83 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -13.23 |
| Trade Value ( ₹ in Lacs) | 0.04 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -6.80 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.71 |
| PAT Margin (%) | -20.83 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -13.23 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 391.38 | 1424.48 |
| Expenses | N/A | N/A |
| PBT | -221.17 | -193.83 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -142.91 | -147.57 |
About Lasa Supergenerics Ltd.
| Founded | 2016 |
|---|---|
| Managing Director | Omkar Pravin Herlekar |
| NSE Symbol | LASA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,67,870.32 | 1,960.15 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,20,945.52 | 8,356.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,906.63 | 5,020.95 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,818.07 | 8,861.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,673.63 | 1,458.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,346.37 | 1,120.55 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,639.01 | 2,380.30 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,086.80 | 1,088.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,193.79 | 2,460.05 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 98,733.25 | 568.15 | 0.00 - 0.00 |
No Records Found
Latest News
Cipla informs about update
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to its intimation dated 10th February, 2026 regarding the Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. (‘InvaGen’), a wholly-owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, Cipla has informed that InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection.
The above information is a part of company’s filings submitted to BSE.
Glaxosmithkline Phar - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 9244.20 | 8048.30 | 14.86 | 9244.20 | 8048.30 | 14.86 | 37902.00 | 37234.90 | 1.79 |
| Other Income | 616.30 | 437.60 | 40.84 | 616.30 | 437.60 | 40.84 | 1425.60 | 1425.60 | 0.00 |
| PBIDT | 3547.90 | 2945.10 | 20.47 | 3547.90 | 2945.10 | 20.47 | 14427.60 | 13118.50 | 9.98 |
| Interest | 9.70 | 4.20 | 130.95 | 9.70 | 4.20 | 130.95 | 27.30 | 13.10 | 108.40 |
| PBDT | 3538.20 | 2940.90 | 20.31 | 3538.20 | 2940.90 | 20.31 | 14426.70 | 13152.30 | 9.69 |
| Depreciation | 158.40 | 155.20 | 2.06 | 158.40 | 155.20 | 2.06 | 664.40 | 667.90 | -0.52 |
| PBT | 3379.80 | 2785.70 | 21.33 | 3379.80 | 2785.70 | 21.33 | 13762.30 | 12484.40 | 10.24 |
| TAX | 846.50 | 738.70 | 14.59 | 846.50 | 738.70 | 14.59 | 3644.10 | 3293.80 | 10.64 |
| Deferred Tax | 33.00 | 0.20 | 16400.00 | 33.00 | 0.20 | 16400.00 | 94.60 | 62.00 | 52.58 |
| PAT | 2533.30 | 2047.00 | 23.76 | 2533.30 | 2047.00 | 23.76 | 10118.20 | 9190.60 | 10.09 |
| Equity | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 |
| PBIDTM(%) | 38.38 | 36.59 | 4.88 | 38.38 | 36.59 | 4.88 | 38.07 | 35.23 | 8.04 |
Park Medi World - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 335.32 | 229.69 | 45.99 | 335.32 | 229.69 | 45.99 | 1289.65 | 915.82 | 40.82 |
| Other Income | 46.68 | 2.01 | 2222.39 | 46.68 | 2.01 | 2222.39 | 103.35 | 20.70 | 399.28 |
| PBIDT | 59.52 | 105.52 | -43.59 | 59.52 | 105.52 | -43.59 | 627.05 | 261.09 | 140.17 |
| Interest | 8.60 | 32.98 | -73.92 | 8.60 | 32.98 | -73.92 | 127.55 | 123.43 | 3.34 |
| PBDT | 50.92 | 72.54 | -29.80 | 50.92 | 72.54 | -29.80 | 499.50 | 137.66 | 262.85 |
| Depreciation | 33.81 | 11.61 | 191.21 | 33.81 | 11.61 | 191.21 | 45.09 | 48.62 | -7.26 |
| PBT | 17.11 | 60.93 | -71.92 | 17.11 | 60.93 | -71.92 | 454.41 | 89.04 | 410.34 |
| TAX | 6.27 | 11.96 | -47.58 | 6.27 | 11.96 | -47.58 | 88.25 | 17.24 | 411.89 |
| Deferred Tax | 2.83 | -0.13 | -2276.92 | 2.83 | -0.13 | -2276.92 | -24.50 | -20.83 | 17.62 |
| PAT | 10.84 | 48.97 | -77.86 | 10.84 | 48.97 | -77.86 | 366.16 | 71.80 | 409.97 |
| Equity | 863.86 | 768.80 | 12.36 | 863.86 | 768.80 | 12.36 | 863.86 | 768.80 | 12.36 |
| PBIDTM(%) | 17.75 | 45.94 | -61.36 | 17.75 | 45.94 | -61.36 | 48.62 | 28.51 | 70.55 |
Artemis MedicareServ - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 2820.10 | 2497.99 | 12.89 | 2820.10 | 2497.99 | 12.89 | 10604.92 | 9132.61 | 16.12 |
| Other Income | 53.96 | 69.58 | -22.45 | 53.96 | 69.58 | -22.45 | 299.05 | 329.15 | -9.14 |
| PBIDT | 608.85 | 478.35 | 27.28 | 608.85 | 478.35 | 27.28 | 2150.30 | 1827.55 | 17.66 |
| Interest | 64.22 | 71.09 | -9.66 | 64.22 | 71.09 | -9.66 | 269.44 | 304.83 | -11.61 |
| PBDT | 544.63 | 407.26 | 33.73 | 544.63 | 407.26 | 33.73 | 1850.12 | 1522.72 | 21.50 |
| Depreciation | 123.53 | 106.60 | 15.88 | 123.53 | 106.60 | 15.88 | 463.28 | 430.18 | 7.69 |
| PBT | 421.10 | 300.66 | 40.06 | 421.10 | 300.66 | 40.06 | 1386.84 | 1092.54 | 26.94 |
| TAX | 110.59 | 86.50 | 27.85 | 110.59 | 86.50 | 27.85 | 352.43 | 257.97 | 36.62 |
| Deferred Tax | 10.18 | 19.22 | -47.03 | 10.18 | 19.22 | -47.03 | 62.12 | 44.75 | 38.82 |
| PAT | 310.51 | 214.16 | 44.99 | 310.51 | 214.16 | 44.99 | 1034.41 | 834.57 | 23.95 |
| Equity | 158.31 | 138.93 | 13.95 | 158.31 | 138.93 | 13.95 | 158.31 | 137.60 | 15.05 |
| PBIDTM(%) | 21.59 | 19.15 | 12.74 | 21.59 | 19.15 | 12.74 | 20.28 | 20.01 | 1.32 |
GPT Healthcare - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 1262.04 | 1071.09 | 17.83 | 1262.04 | 1071.09 | 17.83 | 4725.47 | 4070.91 | 16.08 |
| Other Income | 20.26 | 15.63 | 29.62 | 20.26 | 15.63 | 29.62 | 59.51 | 84.94 | -29.94 |
| PBIDT | 262.07 | 189.29 | 38.45 | 262.07 | 189.29 | 38.45 | 901.34 | 918.48 | -1.87 |
| Interest | 21.63 | 16.33 | 32.46 | 21.63 | 16.33 | 32.46 | 82.40 | 34.71 | 137.40 |
| PBDT | 240.44 | 172.96 | 39.01 | 240.44 | 172.96 | 39.01 | 818.94 | 883.77 | -7.34 |
| Depreciation | 68.81 | 61.82 | 11.31 | 68.81 | 61.82 | 11.31 | 270.88 | 190.30 | 42.34 |
| PBT | 171.63 | 111.14 | 54.43 | 171.63 | 111.14 | 54.43 | 548.06 | 693.47 | -20.97 |
| TAX | 44.33 | 34.32 | 29.17 | 44.33 | 34.32 | 29.17 | 125.85 | 194.24 | -35.21 |
| Deferred Tax | -2.77 | 14.42 | -119.21 | -2.77 | 14.42 | -119.21 | 3.66 | 73.35 | -95.01 |
| PAT | 127.30 | 76.82 | 65.71 | 127.30 | 76.82 | 65.71 | 422.21 | 499.23 | -15.43 |
| Equity | 820.55 | 820.55 | 0.00 | 820.55 | 820.55 | 0.00 | 820.55 | 820.55 | 0.00 |
| PBIDTM(%) | 20.77 | 17.67 | 17.50 | 20.77 | 17.67 | 17.50 | 19.07 | 22.56 | -15.46 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Lasa Supergenerics Ltd. is ₹7.01 as of 2026-08-04.
The market capitalisation of Lasa Supergenerics Ltd. is ₹35.17 as of 2026-08-03.
The 1-year return of Lasa Supergenerics Ltd. is -3.24% as of 2026-08-04.
The P/E ratio of Lasa Supergenerics Ltd. is 0.00 as of 2026-08-04.
The 52-week high and low of Lasa Supergenerics Ltd. are ₹14.08 and ₹5.67, respectively, as of 2026-08-04.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
